{"filing":{"accession_number":"0001178913-26-003617","cik":"0001638097","ticker":"ENTX","company_name":"Entera Bio Ltd.","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-26","primary_document":"zk2635734.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326003617/zk2635734.htm"},"events":[{"id":21093,"run_id":19010,"accession_number":"0001178913-26-003617","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"Entera Bio completed a private placement of 122.96 million ordinary shares and 11.84 million pre-funded warrants for approximately $275 million in aggregate proceeds on July 28, 2026, pursuant to a Securities Purchase Agreement entered into on July 26, 2026. This unregistered equity issuance under Section 4(a)(2) of the Securities Act represents significant dilution to existing shareholders.","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20634,"accession_number":"0001178913-26-003617","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Entera Bio entered into a Securities Purchase Agreement on July 26, 2026, for a private placement of 134.8 million ordinary shares and pre-funded warrants for approximately $275 million in aggregate proceeds. The transaction closed on July 28, 2026, with issuance of 122.96 million ordinary shares and 11.84 million pre-funded warrants. This is a classic unregistered equity issuance under Section 4(a)(2) of the Securities Act, representing significant dilution to existing shareholders and a material capital raise for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:17:06.752552+00:00","company_name":"","ticker":null,"filing_date":""},{"id":20635,"accession_number":"0001178913-26-003617","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 disclosure of unregistered sales of equity securities is the canonical trigger for dilutive_issuance classification. The filing incorporates Item 1.01 by reference, which typically describes material acquisition or capital transaction details. Unregistered equity issuances are material to investors as they dilute existing shareholders and signal capital-raising activity, particularly relevant for smaller-cap biotechnology companies like Entera Bio.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:17:06.752552+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":21094,"run_id":19010,"accession_number":"0001178913-26-003617","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Two independent directors, Haya Taitel and Yonatan Malca, have communicated their intention to resign or not stand for reelection effective upon appointment of replacement directors. This departure is part of an orderly board succession plan.","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20636,"accession_number":"0001178913-26-003617","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on the departure of two independent directors—Haya Taitel and Yonatan Malca—who have communicated they will resign or not stand for reelection effective upon appointment of replacement directors. Although the Item also references new director appointments (BVF Designees and New Independent Directors), the principal action disclosed is the departure of existing board members as part of an orderly succession plan. This is material to investors as it affects board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:17:06.752552+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20634,"accession_number":"0001178913-26-003617","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Entera Bio entered into a Securities Purchase Agreement on July 26, 2026, for a private placement of 134.8 million ordinary shares and pre-funded warrants for approximately $275 million in aggregate proceeds. The transaction closed on July 28, 2026, with issuance of 122.96 million ordinary shares and 11.84 million pre-funded warrants. This is a classic unregistered equity issuance under Section 4(a)(2) of the Securities Act, representing significant dilution to existing shareholders and a material capital raise for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:17:06.752552+00:00","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-28"},{"id":20635,"accession_number":"0001178913-26-003617","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 disclosure of unregistered sales of equity securities is the canonical trigger for dilutive_issuance classification. The filing incorporates Item 1.01 by reference, which typically describes material acquisition or capital transaction details. Unregistered equity issuances are material to investors as they dilute existing shareholders and signal capital-raising activity, particularly relevant for smaller-cap biotechnology companies like Entera Bio.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:17:06.752552+00:00","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-28"},{"id":20636,"accession_number":"0001178913-26-003617","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on the departure of two independent directors—Haya Taitel and Yonatan Malca—who have communicated they will resign or not stand for reelection effective upon appointment of replacement directors. Although the Item also references new director appointments (BVF Designees and New Independent Directors), the principal action disclosed is the departure of existing board members as part of an orderly succession plan. This is material to investors as it affects board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:17:06.752552+00:00","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-28"}]}